Cargando…
Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
N-methyl-d-aspartate (NMDA) receptor hypofunctionality is a well-studied hypothesis for schizophrenia pathophysiology, and daily dosing of the NMDA receptor co-agonist, d-serine, in clinical trials has shown positive effects in patients. Therefore, inhibition of d-amino acid oxidase (DAAO) has the p...
Autores principales: | Fradley, Rosa, Goetghebeur, Pascal, Miller, David, Burley, Russell, Almond, Sarah, Gruart i Massó, Agnès, Delgado García, José M., Zhu, Bin, Howley, Eimear, Neill, Jo C., Grayson, Ben, Gaskin, Philip, Carlton, Mark, Gray, Ian, Serrats, Jordi, Davies, Ceri H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471729/ https://www.ncbi.nlm.nih.gov/pubmed/37289348 http://dx.doi.org/10.1007/s11064-023-03956-2 |
Ejemplares similares
-
Correction to: Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
por: Fradley, Rosa, et al.
Publicado: (2023) -
The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
por: O’Donnell, Patricio, et al.
Publicado: (2023) -
Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia
por: Wang, Hao, et al.
Publicado: (2021) -
Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
por: Yoneyama, Tomoki, et al.
Publicado: (2020) -
Effects of β-Hydroxy β-Methylbutyrate Supplementation on Working Memory and Hippocampal Long-Term Potentiation in Rodents
por: Barranco, Alejandro, et al.
Publicado: (2022)